Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tumor: early-phase trial registry
8 of 19 indexed Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 8 currently recruiting · #902 of 28,707 conditions by registered trial count
Tumor: 19 US clinical trials tracked, 8 recruiting.
Tumor is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition tumor
OPEN 8 | RECR 42% | LATE 0 | EARLY 12 | RANK #902 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Brain Concussion (42% recruiting · 19 trials)
Tumor lists 8 open slots (42% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tumor is recruiting below its size-band peers.
8 of 19 indexed trials (42.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tumor research.
M.D. Anderson Cancer Center accounts for 7 of 19 trials (36.8%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Tumor enrolment sits around 67 participants.
Median target enrolment is 67 among the 19 trials that report a genuine target (sentinel values excluded). 11 of those (57.9%) plan for fewer than 100 participants.
-
Tumor research is mostly interventional.
14 interventional and 5 observational studies make up this index (73.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Decoupling Immunotherapy Toxicity and Cancer Response
M.D. Anderson Cancer Center
NCT07382752
A Study of Live Tumor Fragments of Surgical Resections
Mayo Clinic
NCT07000864
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
NCT05064280
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
NCT05879146
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
NCT06108232
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience
NCT05997017
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Aadi Bioscience
NCT05661461
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Leslie Ballas
NCT06417190
Evaluation of Proton Therapy in Pediatric Cancer Patients
St. Jude Children's Research Hospital
NCT03223766
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Loren Mell, MD
NCT03383094
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
HistoSonics
NCT05820087
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
NCT00463814
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT05470283
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
NCT05273554
High-density EEG in Neurological Disorders
Dartmouth-Hitchcock Medical Center
NCT04266041
MaxAn Post Market Surveillance Validation
Zimmer Biomet
NCT01343693
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Nektar Therapeutics
NCT00802945
Radiation Therapy and Cardiac Enzymes
M.D. Anderson Cancer Center
NCT00777751
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tumor page
19 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Tumor trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tumor condition card totals 19 registered trials; most-linked intervention nab-sirolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.